Evommune, Inc. Operating Cash Flow
Evommune, Inc. (EVMN) reported Operating Cash Flow of -$47.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Evommune, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$20.32M.
- Evommune, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$27.50M.
- Evommune, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$16.70M.
- Evommune, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.63M.
- Evommune, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$76.44M.
- Evommune, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$58.20M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$47.82M 10-Q · filed 2026-08-06 | -$64.52M derived: sum of 3 quarters · filed 2026-08-06 | -$74.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$27.50M 10-Q · filed 2026-05-07 | -$44.20M derived: sum of 2 quarters · filed 2026-05-07 | -$53.84M derived: sum of 3 quarters · filed 2026-05-07 | -$80.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$16.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$26.33M derived: sum of 2 quarters · filed 2026-03-05 | -$52.54M derived: sum of 3 quarters · filed 2026-08-06 | -$76.44M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$9.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-11 | -$35.84M derived: sum of 2 quarters · filed 2026-08-06 | -$59.74M 10-Q · filed 2025-12-11 | -$78.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$26.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$50.11M 10-Q · filed 2026-08-06 | -$68.62M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$23.90M 10-Q · filed 2026-05-07 | -$42.41M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$18.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$58.20M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$39.68M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |